Biogen Beats Q2 Estimates as Newer Drugs Drive Growth Biogen reports $2.74B Q2 revenue, up 3% and beating estimates. Growth products surge 24%, rare-disease drugs rise 11%. Credit: Scott Eisen/Bloomberg Subscribe now Already have an account? Sign in.
